CN102166141A - Process for preparing drug eluting stent - Google Patents
Process for preparing drug eluting stent Download PDFInfo
- Publication number
- CN102166141A CN102166141A CN2010102454250A CN201010245425A CN102166141A CN 102166141 A CN102166141 A CN 102166141A CN 2010102454250 A CN2010102454250 A CN 2010102454250A CN 201010245425 A CN201010245425 A CN 201010245425A CN 102166141 A CN102166141 A CN 102166141A
- Authority
- CN
- China
- Prior art keywords
- bracket
- eluting medicament
- preparation technology
- coating
- ethylene oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 134
- 229940079593 drug Drugs 0.000 title abstract description 41
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 238000000576 coating method Methods 0.000 claims abstract description 59
- 239000011248 coating agent Substances 0.000 claims abstract description 55
- 230000001954 sterilising effect Effects 0.000 claims abstract description 49
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000005516 engineering process Methods 0.000 claims description 36
- 238000002360 preparation method Methods 0.000 claims description 33
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 30
- 238000012856 packing Methods 0.000 claims description 26
- 238000004659 sterilization and disinfection Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 239000004310 lactic acid Substances 0.000 claims description 15
- 235000014655 lactic acid Nutrition 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 230000008602 contraction Effects 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000003825 pressing Methods 0.000 abstract 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 9
- 208000037803 restenosis Diseases 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 7
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 7
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 7
- 229960002930 sirolimus Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 5
- 238000005336 cracking Methods 0.000 description 5
- 239000004626 polylactic acid Substances 0.000 description 5
- 206010027336 Menstruation delayed Diseases 0.000 description 4
- 229920002988 biodegradable polymer Polymers 0.000 description 4
- 239000004621 biodegradable polymer Substances 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010894 electron beam technology Methods 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920006237 degradable polymer Polymers 0.000 description 2
- QCUFYOBGGZSFHY-UHFFFAOYSA-N depsidomycin Chemical compound O=C1C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC=O)C(C)CC)C(C)OC(=O)C2CCCNN2C(=O)C(CC(C)C)NC(=O)C2CCCNN21 QCUFYOBGGZSFHY-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- -1 KanglemycinC Chemical compound 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- GDVNLLJNADMLLR-BBRMVZONSA-N Spergualin Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)C[C@@H](O)CCCCN=C(N)N GDVNLLJNADMLLR-BBRMVZONSA-N 0.000 description 1
- JBVZQDJNGFOSNX-UHFFFAOYSA-N Spergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CC(O)CCCCNC(=CN)N JBVZQDJNGFOSNX-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 108010017278 depsidomycin Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- KHYBPSFKEHXSLX-UHFFFAOYSA-N iminotitanium Chemical compound [Ti]=N KHYBPSFKEHXSLX-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Abstract
The invention provides a process for preparing a drug eluting stent, which can effectively increase the stability of a drug eluting stent coating. The process for preparing the drug eluting stent comprises the following steps of: (1) pre-treating a naked stent; (2) coating to form a coating; (3) sterilizing by using ethylene oxide; (4) mounting a balloon; (5) pressing and holding the stent; and (6) internally packaging. After the drug eluting stent is pressed and held on the balloon, the adhesion between the balloon and the coating is avoided; and the coating has a complete surface and adherence tightness after the drug eluting stent is expanded by a balloon expander.
Description
Technical field
The present invention relates to a kind of preparation technology of bracket for eluting medicament, particularly a kind of preparation technology with bracket for eluting medicament of stable coatings.
Background technology
Extensive use along with the intracoronary stent implantation, the development of the increase of clinical case number, the prolongation of following up a case by regular visits to the time and intravascular ultrasound technology, in-stent restenosis (ISR) problem just exposes gradually and more and more comes into one's own, and has become the research emphasis that gets involved the cardiology field.In bare metal stent (BMS) epoch, the incidence rate of in-stent restenosis is up to 20%～30%, and main cause is the endothelium hyperplasia that support is inserted the position.The appearance of bracket for eluting medicament (DES) has solved this problem well, it is by inserting the local medicine that discharges at support, reach inflammation-inhibiting, suppress smooth muscle cell proliferation and effects such as migration, minimizing endotheliocyte hyper-proliferative, thereby reduce narrow generation in the support.
Bracket for eluting medicament is that medicine directly or by appropriate carriers is applied to metal support surface, becomes the local delivery system of medicine, and carrier has two kinds of degradable and non-degradable materials.In bracket for eluting medicament, discharge by drug slow and to suppress in-stent restenosis.The preparation technology of bracket for eluting medicament comprises the bare bracket pretreatment, and applying coating is installed sacculus, pressure is held support, sterilization, inner packing etc., traditional preparation technology's flow process are generally bare bracket pretreatment → applying coating → installation sacculus → pressure and hold support → inner packing → sterilization.The degradation material coating bracket finds that drug stent carries out ethylene oxide sterilizing after the foley's tube pressure is held in production process, again through the balloon dilatation catheter expansion, find the coating cracking of support inner surface or come off the integrity of destruction coating.
In order to solve the phenomenon that the DES coating ftractures or comes off after the balloon dilatation catheter expansion, CN1533813A (application number is CN03116063.8) discloses a kind of coating stent of medicine of preventing/treating percutaneous transluminal coronary shaping postoperative restenosis, description is described " for to prevent because of the adhesion between medication coat and the sacculus; can be earlier be coated with last layer Parylene (Parylene) or derivatives thereof in the method for rack surface by vapour deposition, its THICKNESS CONTROL is between the 0.01-10 micron ".Adopt the DES product of the method to have at present, as: the Cypher support that Johnson Co. produces, its drug-loaded layer is PEVA/PBMA non-degradable polymer+Parylene; The BioMatrix support that Singapore Biosensors International company produces, its drug-loaded layer is polylactic acid biodegradable polymers+Parylene; The Axxess support that U.S. DEVAX produces, its drug-loaded layer is polylactic acid biodegradable polymers+Parylene; And the Bobori support produced of Japanese TERUMO company, its drug-loaded layer is polylactic acid biodegradable polymers+Parylene, etc.Parylenes etc. are the non-degradable polymer, yet patient's endothelium healing delay is found in increasing clinical research, chronic inflammatory reaction, adherent bad and late period in late period adverse events such as restenosis, may be because the extended residual of DES drug-carrying polymer causes, therefore, the present invention adopts the totally biodegradable polymer to prepare bracket for eluting medicament as drug-loaded layer.
In order to realize not using nondegradable polymer to do bottom, can guarantee to expand through balloon dilatation catheter behind the drug stent ethylene oxide sterilizing, medication coat and sacculus do not stick together yet again, and outward appearance is complete, the adherent purpose closely of coating needs research and development better medicament FirebirdTM preparation technology.
Summary of the invention
The object of the present invention is to provide a kind of preparation technology of bracket for eluting medicament, this technology can effectively improve the stability of bracket for eluting medicament coating.Avoided the bracket for eluting medicament system that uses ethylene oxide sterilizing to cross, again through balloon dilatation catheter expansion, the possibility that medication coat and sacculus stick together easily; After bracket for eluting medicament is placed in the human vas stenosis, the integrity of coating can guarantee the performance of flushing of anti-blood flow that coating is good, thereby avoided because of coating cracking or blood flow wash away fractionlet in the process come off cause inflammatory reaction may, reduce the generation of untoward reaction such as the interior restenosis of blood vessel in late period, avoided the formation of advanced thrombus.
Purpose of the present invention is achieved through the following technical solutions: a kind of preparation technology of bracket for eluting medicament, bracket for eluting medicament is made of bare bracket and the coating that is coated on the support, it is characterized in that: described preparation technology sterilized before pressure is held for bracket for eluting medicament, and described sterilization is an ethylene oxide sterilizing.
The preparation technology of said medicine FirebirdTM carried out ethylene oxide sterilizing for bracket for eluting medicament before sacculus is installed.
The preparation technology of said medicine FirebirdTM carries out ethylene oxide sterilizing for bracket for eluting medicament after applying coating.
The preparation technology of said medicine FirebirdTM is (1) bare bracket pretreatment; (2) applying coating; (3) ethylene oxide sterilizing; (4) sacculus is installed; (5) pressure is held support; (6) inner packing.
The preparation technology of said medicine FirebirdTM is (1) bare bracket pretreatment: bare bracket cleans, drying; (2) applying coating: coated carrier is dissolved in the solvent, mix homogeneously, evenly be coated on rack surface, then 25 ℃～50 ℃ dryings 12～72 hours, described solvent is a kind of in acetone, chloroform, oxolane, the dichloromethane, and described coating method of coating is infusion process or spraying process; (3) ethylene oxide sterilizing: bracket for eluting medicament after drying, bracket for eluting medicament, foley's tube and packing inside bag carry out ethylene oxide sterilizing; (4) sacculus is installed: bracket for eluting medicament is installed on sacculus; (5) pressure is held support: support is implemented to press hold operation; (6) inner packing: the sacculus and the bracket for eluting medicament that are in contraction state are packaged in the packing inside bag under aseptic condition.
Above-mentioned solvent is a kind of in acetone, chloroform, oxolane, the dichloromethane.
Above-mentioned coating method of coating is infusion process or spraying process.
Above-mentioned ethylene oxide sterilizing adopts the air bells laid method.
Above-mentioned sterilization is carried out under specific temperature conditions, preferred 25 ℃-50 ℃.
Above-mentioned coated carrier is a Biodegradable material, can be Poly-L-lactic acid (PLLA), polylactic-co-glycolic acid (PLGA), poly-dl-lactide (PDLLA), preferred polylactic-co-glycolic acid (PLGA).
The molecular weight of above-mentioned polylactic-co-glycolic acid (PLGA) is 50,000～250,000, is preferably 50,000～100,000.
The molecule lactic acid and the glycolic proportion of composing of above-mentioned polylactic-co-glycolic acid (PLGA) are, lactic acid (LA): glycolic (GA)=50%～90%: 50%～10%, preferred LA: GA=50%～85%: 50%～15%, wherein lactic acid and glycolic molar percentage meter.
Above-mentioned coating is loaded with the medicine of therapeutic dose, comprises in anti-oxidation medicine, anticoagulation class medicine, anticancer class medicine, inhibition vascular smooth muscle cell curing class medicine, anti-inflammatory drug or the immune suppressant drug one or more.
Above-mentioned anti-oxidation medicine comprises superoxide dismutase, catalase, coenzyme Q10, glutathion peroxidase; Anticoagulation class medicine comprises aspirin, heparin, clopidogrel etc.; Anticancer class medicine comprises colchicine, paclitaxel; Suppress vascular smooth muscle cell curing class medicine and comprise angiogenic peptide, 17-hydroxy-11-dehydrocorticosterone, calcium ion antagonist; Anti-inflammatory drug comprises dactinomycin, Depsidomycin, KanglemycinC, Spergualin, Mytiocin, Gllooxin; Immune suppressant drug comprises rapamycin, Ciclosporin A, ciclosporin C, brefeldin A.
Said medicine and coated carrier mass ratio are 1: 10～2: 1, are preferably 1: 3～1: 1.
The material of above-mentioned bare bracket is any one of rustless steel, Ni-Ti alloy, cochrome or macromolecular material.
The sterilization of support has the air sedimentation usually, radiation sterilization and chemical reagent infusion process etc.Bracket for eluting medicament particularly is loaded with the support of biodegradable coating and medicine, adopt radiation sterilization, regular meeting influences medicament contg because of the energy height of radiation electric ion destroys medicines structure, high radiant energy destroys the integrity of coating easily because of surpassing the vitrification point of polymer simultaneously; The chemical reagent infusion process also can influence the stable and drug release of coating, and can bring certain dissolvent residual; The sterilization of air bells laid method can be carried out under lower temperature conditions, is particularly suitable for heat-labile material is sterilized, and the sterilization of air bells laid method adopts sterilization material to mainly contain formaldehyde and oxirane etc.Therefore, the present invention adopts and adopt the sterilization of air bells laid method, sterilization material optimization ethylene oxide under 25 ℃ of-50 ℃ of temperature conditions.
Biodegradable material polylactic acid-glycollic acid (PLGA) is synthetic by ring opening copolymer by polylactic acid (PLA) and poly-Acetic acid, hydroxy-, bimol. cyclic ester (PGA).Polylactic acid (PLA) and poly-Acetic acid, hydroxy-, bimol. cyclic ester (PGA) belong to polylactone family macromolecule material together, nontoxic, good biocompatibility, and hydrolysis can take place after meeting water in the ester bond that exists in their molecular backbones, cause molecular backbone fracture, molecular weight to reduce, and the final degradation product, glycolic acid of poly-Acetic acid, hydroxy-, bimol. cyclic ester and polylactide and lactic acid can be become carbon dioxide and water in vivo and excretes by tricarboxylic acid cycle, so these two kinds of polylactone family macromolecule materials all can finally disappear in body owing to the biodegradation of material after implanting fully.Because PLGA has good biological property, the preferred PLGA of the present invention is as pharmaceutical carrier.
The present invention has following advantage and beneficial effect compared to existing technology:
1, compares with the like product that goes on the market, expand through balloon dilatation catheter again behind the drug stent ethylene oxide sterilizing of the present invention, medication coat does not stick together with sacculus, complete appearance, adherent tight, effectively improved coating abrasion resistance energy, thus the possibility of avoiding coating cracking or washing away the fractionlet that comes off in the process at blood flow, reduce the generation of untoward reaction such as the interior restenosis of blood vessel in late period, avoided the formation of advanced thrombus.
2, avoid using nondegradable polymer to do bottom, reduce the incidence rate that increases thrombosis and in-stent restenosis in the later stage support because of untoward reaction such as endothelium healing delay, chronic inflammatory diseases.
3, preparation technology of the present invention has improved the qualification rate of bracket for eluting medicament system, reduces production costs.
Description of drawings
Fig. 1: preparation technology's flow chart of bracket for eluting medicament of the present invention
Fig. 2: the traditional preparation process process chart of bracket for eluting medicament
Fig. 3: the preparation technology's flow chart that adopts the bracket for eluting medicament of the present invention of electron beam sterilization method
Preparation technology's flow chart of the open bracket for eluting medicament of Fig. 4: CN1533813A
The specific embodiment
The present invention is described in further detail below in conjunction with embodiment and accompanying drawing, but the working of an invention mode is not limited thereto.
Embodiment 1: shown in accompanying drawing 1, (1) bare bracket pretreatment: bare bracket cleans, drying; (2) applying coating: with lactic acid---ethanol copolymer (PLGA, lactic acid/glycolic=50/50, molecular weight 100000) is dissolved in and makes 2.0wt% solution in the acetone, and drug rapamycin is dissolved in wherein makes 1.0wt% solution, spray to the cochrome rack surface, make drug loading reach requirement (about 40～200 μ g/mm), the dry drug support is 24 hours again; (3) ethylene oxide sterilizing: bracket for eluting medicament, foley's tube and packing inside bag are extremely aseptic 40 ℃ of following ethane via epoxyethane sterilizations; (4) sacculus is installed: bracket for eluting medicament is installed on sacculus; (5) pressure is held support: press the merosystolic state of sacculus that bracket for eluting medicament is arranged to foley's tube of holding; (6) inner packing: will press the bracket for eluting medicament system of holding to be packaged in the packing inside bag.
Expand by balloon dilatation catheter, it is apparent that 40 power microscopes are observed coating down, support inner surface and external surface coating complete appearance.
Embodiment 2: shown in accompanying drawing 2, (1) bare bracket pretreatment: bare bracket cleans, drying; (2) applying coating: with lactic acid---ethanol copolymer (PLGA, lactic acid/glycolic=50/50, molecular weight 100000) is dissolved in and makes 2.0wt% solution in the acetone, and drug rapamycin is dissolved in wherein makes 1.0wt% solution, spray to the cochrome rack surface, make drug loading reach requirement (about 40～200 μ g/mm), the dry drug support is 24 hours again; (3) sacculus is installed: bracket for eluting medicament is installed on sacculus; (4) pressure is held support: press the merosystolic state of sacculus that bracket for eluting medicament is arranged to foley's tube of holding; (5) inner packing: will press the bracket for eluting medicament system of holding to be packaged in the packing inside bag; (6) ethylene oxide sterilizing: extremely aseptic 40 ℃ of following ethane via epoxyethane sterilization sterilizations.
Expand by balloon dilatation catheter, the observation coating is apparent down for 40 power microscopes, and the inner surface of coating bracket has the small size coating to be glued by sacculus, and the coating at the big ripple of support place has cracking.
Embodiment 3: shown in accompanying drawing 3, (1) bare bracket pretreatment: bare bracket cleans, drying; (2) applying coating: with lactic acid---ethanol copolymer (PLGA, lactic acid/glycolic=50/50, molecular weight 100000) is dissolved in and makes 2.0wt% solution in the acetone, and drug rapamycin is dissolved in wherein makes 1.0wt% solution, spray to the cochrome rack surface, make drug loading reach requirement (about 40～200 μ g/mm), the dry drug support is 24 hours again; (3) electron beam sterilization: bracket for eluting medicament, foley's tube and packing inside bag are after electron beam sterilization is extremely aseptic; (4) sacculus is installed: bracket for eluting medicament is installed on sacculus; (5) pressure is held support: press the merosystolic state of sacculus that bracket for eluting medicament is arranged to foley's tube of holding; (6) inner packing: will press the bracket for eluting medicament system of holding to be packaged in the packing inside bag.
Expand by balloon dilatation catheter, the observation coating is apparent down for 40 power microscopes, and the inner surface of coating bracket is kept perfectly, and the coating of outer surface and the big ripple of support all has obvious cracking.
Embodiment 4: shown in accompanying drawing 4, (1) bare bracket pretreatment: bare bracket cleans, drying; (2) apply Parylene and make bottom: utilize vapour deposition process, do bottom at cochrome bare bracket surface-coated Parylene; (3) applying coating: with lactic acid---ethanol copolymer (PLGA, lactic acid/glycolic=50/50, molecular weight 100000) is dissolved in and makes 2.0wt% solution in the acetone, and drug rapamycin is dissolved in wherein makes 1.0wt% solution, spray to the cochrome rack surface, make drug loading reach requirement (about 40～200 μ g/mm), the dry drug support is 24 hours again; (4) sacculus is installed: bracket for eluting medicament is installed on sacculus; (5) pressure is held support: press the merosystolic state of air bag that bracket for eluting medicament is arranged to balloon catheter of holding; (6) inner packing: will press the bracket for eluting medicament system of holding to be packaged in the packing inside bag; (7) ethylene oxide sterilizing: extremely aseptic 40 ℃ of following ethane via epoxyethane sterilizations.
Expand by balloon expandable, it is apparent that 40 power microscopes are observed coating down, support inner surface and external surface coating complete appearance.
Embodiment 5: shown in accompanying drawing 1, (1) bare bracket pretreatment: bare bracket cleans, drying; (2) applying coating: with lactic acid---ethanol copolymer (PLGA, lactic acid/glycolic=85/15, molecular weight 50000) is dissolved in and makes 3.0wt% solution in the chloroform, and drug rapamycin is dissolved in wherein makes 1.0wt% solution, spray to the cochrome rack surface, make drug loading reach requirement (about 40～200 μ g/mm), the dry drug support is 12 hours again; (3) ethylene oxide sterilizing: bracket for eluting medicament, foley's tube and packing inside bag are extremely aseptic 25 ℃ of following ethane via epoxyethane sterilizations; (4) sacculus is installed: bracket for eluting medicament is installed on sacculus; (5) pressure is held support: press the merosystolic state of sacculus that bracket for eluting medicament is arranged to foley's tube of holding; (6) inner packing: will press the bracket for eluting medicament system of holding to be packaged in the packing inside bag.
Expand by balloon dilatation catheter, it is apparent that 40 power microscopes are observed coating down, support inner surface and external surface coating complete appearance.
Embodiment 6: shown in accompanying drawing 1, (1) bare bracket pretreatment: bare bracket cleans, drying; (2) applying coating: with lactic acid---ethanol copolymer (PLGA, lactic acid/glycolic=75/25, molecular weight 75000) is dissolved in and makes 1.0wt% solution in the oxolane, and drug rapamycin is dissolved in wherein makes 1.0wt% solution, spray to the cochrome rack surface, make drug loading reach requirement (about 40～200 μ g/mm), the dry drug support is 72 hours again; (3) ethylene oxide sterilizing: bracket for eluting medicament, foley's tube and packing inside bag are extremely aseptic 50 ℃ of following ethane via epoxyethane sterilizations; (4) sacculus is installed: bracket for eluting medicament is installed on sacculus; (5) pressure is held support: press the merosystolic state of sacculus that bracket for eluting medicament is arranged to foley's tube of holding; (6) inner packing: will press the bracket for eluting medicament system of holding to be packaged in the packing inside bag.
Expand by balloon dilatation catheter, it is apparent that 40 power microscopes are observed coating down, support inner surface and external surface coating complete appearance.
The foregoing description is a preferred implementation of the present invention; but embodiments of the present invention are not restricted to the described embodiments; other any do not deviate from change, the modification done under spirit of the present invention and the principle, substitutes, combination, simplify; all should be the substitute mode of equivalence, be included within protection scope of the present invention.
Claims (10)
1. the preparation technology of a bracket for eluting medicament, bracket for eluting medicament is made of bare bracket and the coating that is coated on the support, and it is characterized in that: described preparation technology sterilized before pressure is held for bracket for eluting medicament, and described sterilization is an ethylene oxide sterilizing.
2. the preparation technology of a kind of bracket for eluting medicament as claimed in claim 1 is characterized in that: the preparation technology of described bracket for eluting medicament carried out ethylene oxide sterilizing for bracket for eluting medicament before sacculus is installed.
3. the preparation technology of a kind of bracket for eluting medicament as claimed in claim 1, it is characterized in that: the preparation technology of described bracket for eluting medicament carries out ethylene oxide sterilizing for bracket for eluting medicament after applying coating.
4. as the preparation technology of the described a kind of bracket for eluting medicament of the arbitrary claim of claim 1～3, it is characterized in that: the preparation technology of described bracket for eluting medicament is (1) bare bracket pretreatment; (2) applying coating; (3) ethylene oxide sterilizing; (4) sacculus is installed; (5) pressure is held support; (6) inner packing.
5. as the preparation technology of any described a kind of bracket for eluting medicament of claim 1～3, it is characterized in that: described ethylene oxide sterilizing adopts the air bells laid method, and sterilising temp is 25 ℃-50 ℃.
6. the preparation technology of a kind of bracket for eluting medicament as claimed in claim 4, it is characterized in that: the preparation technology of described bracket for eluting medicament is (1) bare bracket pretreatment: bare bracket cleans, drying; (2) applying coating: coated carrier is dissolved in the solvent, mix homogeneously, evenly be coated on rack surface, then 25 ℃～50 ℃ dryings 12～72 hours, described solvent is a kind of in acetone, chloroform, oxolane, the dichloromethane, and described coating method of coating is infusion process or spraying process; (3) ethylene oxide sterilizing: bracket for eluting medicament after drying, bracket for eluting medicament, foley's tube and packing inside bag carry out ethylene oxide sterilizing; (4) sacculus is installed: bracket for eluting medicament is installed on sacculus; (5) pressure is held support: support is implemented to press hold operation; (6) inner packing: the sacculus and the bracket for eluting medicament that are in contraction state are packaged in the packing inside bag under aseptic condition.
7. the preparation technology of a kind of bracket for eluting medicament as claimed in claim 6 is characterized in that: described ethylene oxide sterilizing adopts the air bells laid method, and sterilising temp is 25 ℃-50 ℃.
8. as the preparation technology of the described a kind of bracket for eluting medicament of the arbitrary claim of claim 1～7, it is characterized in that: described coated carrier is the Biodegradable material polylactic-co-glycolic acid.
9. the preparation technology of a kind of bracket for eluting medicament as claimed in claim 8, it is characterized in that: the molecular weight of described polylactic-co-glycolic acid is 50,000～100,000, the lactic acid of described polylactic-co-glycolic acid and glycolic proportion of composing are, lactic acid: glycolic=50%～85%: 50%～15%, wherein lactic acid and glycolic are in molar percentage.
10. as the preparation technology of the described a kind of bracket for eluting medicament of the arbitrary claim of claim 1～9, it is characterized in that: the mass ratio of described medicine and coated carrier is 1: 3～1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102454250A CN102166141B (en) | 2010-07-30 | 2010-07-30 | Process for preparing drug eluting stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102454250A CN102166141B (en) | 2010-07-30 | 2010-07-30 | Process for preparing drug eluting stent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102166141A true CN102166141A (en) | 2011-08-31 |
| CN102166141B CN102166141B (en) | 2013-08-21 |
Family
ID=44487590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102454250A Active CN102166141B (en) | 2010-07-30 | 2010-07-30 | Process for preparing drug eluting stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102166141B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013043429A1 (en) * | 2011-09-19 | 2013-03-28 | Abbott Cardiovascular Systems Inc. | Cold ethylene oxide sterilization of a biodegradable polymeric stent |
| CN103334070A (en) * | 2013-06-24 | 2013-10-02 | 中国科学院金属研究所 | Method for improving usability of biomedical degradable magnesium alloy cardiovascular stent |
| WO2014040542A1 (en) * | 2012-09-12 | 2014-03-20 | 上海微创医疗器械（集团）有限公司 | Low temperature sterilization method suitable for biodegradable stent |
| CN104083806A (en) * | 2014-06-13 | 2014-10-08 | 江西中医药大学 | Drug coating used for drug eluting stent and preparation method and application thereof |
| CN104524646A (en) * | 2014-06-03 | 2015-04-22 | 东莞天天向上医疗科技有限公司 | Biodegradable drug eluting stent and manufacturing method thereof |
| CN106474507A (en) * | 2016-10-19 | 2017-03-08 | 深圳市信立泰生物医疗工程有限公司 | A kind of sterilization process improving polymer support medication coat stability |
| CN107158483A (en) * | 2017-07-12 | 2017-09-15 | 上海微特生物技术有限公司 | A kind of sterile working method for improving biodegradable stent systematic function |
| CN107811726A (en) * | 2016-09-13 | 2018-03-20 | 先健科技(深圳)有限公司 | Overlay film frame |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105142688B (en) | 2014-02-04 | 2018-01-19 | 艾博特心血管系统公司 | Cause novolimus and drug delivery stent or support member of the coating with minimum bonded amount with the coating based on novolimus and lactide |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008098418A1 (en) * | 2007-02-14 | 2008-08-21 | Shandong Intech Medical Technology Co., Ltd. | Intracoronary stent with asymmetric drug releasing controlled coating |
| CN101711710A (en) * | 2009-11-25 | 2010-05-26 | 深圳市信立泰生物医疗工程有限公司 | Medicament eluting stent and preparation method thereof |
| CN101745153A (en) * | 2010-01-21 | 2010-06-23 | 万瑞飞鸿(北京)医疗器材有限公司 | Cobalt-chromium alloy artery stent with full-biodegradation medicine coating, stent system and preparation method thereof |
-
2010
- 2010-07-30 CN CN2010102454250A patent/CN102166141B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008098418A1 (en) * | 2007-02-14 | 2008-08-21 | Shandong Intech Medical Technology Co., Ltd. | Intracoronary stent with asymmetric drug releasing controlled coating |
| CN101711710A (en) * | 2009-11-25 | 2010-05-26 | 深圳市信立泰生物医疗工程有限公司 | Medicament eluting stent and preparation method thereof |
| CN101745153A (en) * | 2010-01-21 | 2010-06-23 | 万瑞飞鸿(北京)医疗器材有限公司 | Cobalt-chromium alloy artery stent with full-biodegradation medicine coating, stent system and preparation method thereof |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013043429A1 (en) * | 2011-09-19 | 2013-03-28 | Abbott Cardiovascular Systems Inc. | Cold ethylene oxide sterilization of a biodegradable polymeric stent |
| WO2014040542A1 (en) * | 2012-09-12 | 2014-03-20 | 上海微创医疗器械（集团）有限公司 | Low temperature sterilization method suitable for biodegradable stent |
| CN103656701A (en) * | 2012-09-12 | 2014-03-26 | 上海微创医疗器械（集团）有限公司 | Low-temperature sterilizing method suitable for biodegradable scaffold |
| CN103334070A (en) * | 2013-06-24 | 2013-10-02 | 中国科学院金属研究所 | Method for improving usability of biomedical degradable magnesium alloy cardiovascular stent |
| CN103334070B (en) * | 2013-06-24 | 2016-01-13 | 中国科学院金属研究所 | Improve biological medical degradable magnesium alloy angiocarpy bracket use properties method |
| CN104524646A (en) * | 2014-06-03 | 2015-04-22 | 东莞天天向上医疗科技有限公司 | Biodegradable drug eluting stent and manufacturing method thereof |
| CN104083806A (en) * | 2014-06-13 | 2014-10-08 | 江西中医药大学 | Drug coating used for drug eluting stent and preparation method and application thereof |
| CN104083806B (en) * | 2014-06-13 | 2016-04-27 | 江西中医药大学 | A kind of medication coat for bracket for eluting medicament and its preparation method and application |
| CN107811726A (en) * | 2016-09-13 | 2018-03-20 | 先健科技(深圳)有限公司 | Overlay film frame |
| CN106474507A (en) * | 2016-10-19 | 2017-03-08 | 深圳市信立泰生物医疗工程有限公司 | A kind of sterilization process improving polymer support medication coat stability |
| CN107158483A (en) * | 2017-07-12 | 2017-09-15 | 上海微特生物技术有限公司 | A kind of sterile working method for improving biodegradable stent systematic function |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102166141B (en) | 2013-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102166141B (en) | Process for preparing drug eluting stent | |
| JP4758474B2 (en) | Coating the entire surface of a vascular stent | |
| JP5689377B2 (en) | Manufacturing, methods, and uses of drug eluting medical devices for permanently opening blood vessels | |
| US8092819B2 (en) | Implantable medical device coated with a bioactive agent | |
| US20040034409A1 (en) | Stent with polymeric coating | |
| US20050060028A1 (en) | Coating of stents for preventing restenosis | |
| CN103948975B (en) | A kind of targeted drug release gets involved class medical apparatus and instruments and preparation method thereof | |
| US20100137975A1 (en) | Active-substance-coated medical product, method for its production and its uses | |
| CN101869723A (en) | Composite medicament stent for inhibiting cardiovascular restenosis and preparation method | |
| CN102058893B (en) | There is the electron beam sterilization of the medical treatment device of bioactivity coatings | |
| JP2008289853A (en) | Coating agent for medical equipment which has anti-thrombus conjugate | |
| CN101199872A (en) | Double medicament controlled-release coating micropore ACS bracket | |
| CN101091806A (en) | Slow release coating layer of degradable medication for bracket of coronary artery | |
| CN101264345A (en) | Degradable blood vessel stent drug-eluting capable of reducing incidence rate of advanced thrombus | |
| CN101711710B (en) | Medicament eluting stent and preparation method thereof | |
| US9737395B2 (en) | Systems and methods for reducing scarring | |
| JP2011019918A (en) | Coating for medical device having anti-thrombotic conjugate | |
| Sydow-Plum et al. | Review of stent coating strategies: clinical insights | |
| CN108465129A (en) | The medical treatment device of drug coat | |
| JP2016523588A (en) | Hollow stent filled with therapeutic compound formulation | |
| CN201143321Y (en) | Vascular undercoat stent | |
| CN103687633A (en) | Implantable vascular stent | |
| KR102409251B1 (en) | Drug-eluting stent | |
| JP2006262960A (en) | Stent | |
| CN1524590A (en) | Medicament elution interventional medical apparatus and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 518118, No. five, No. 1, great industrial zone, Ping Shan, Guangdong, Shenzhen Patentee after: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. Address before: Baoan District Xixiang street Shenzhen city Guangdong province 518102 115 City District 1 factories Patentee before: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 518118 No.1, Guihua 5th Road, Pingshan District, Shenzhen City, Guangdong Province Patentee after: Shenzhen Xinlitai Medical Equipment Co.,Ltd. Address before: 518118 No.1, Guihua 5th Road, Pingshan District, Shenzhen City, Guangdong Province Patentee before: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231120 Address after: No.16 Chunlin Street, Daxing Biomedical Industry Base, Zhongguancun Science and Technology Park, Daxing District, Beijing, 102629 Patentee after: YALUN BIOTECHNOLOGY (BEIJING) Co.,Ltd. Address before: 518118 No.1, Guihua 5th Road, Pingshan District, Shenzhen City, Guangdong Province Patentee before: Shenzhen Xinlitai Medical Equipment Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: No.16 Chunlin Street, Daxing Biomedical Industry Base, Zhongguancun Science and Technology Park, Daxing District, Beijing, 102629 Patentee after: Beijing Xinlitai Medical Equipment Co.,Ltd. Address before: No.16 Chunlin Street, Daxing Biomedical Industry Base, Zhongguancun Science and Technology Park, Daxing District, Beijing, 102629 Patentee before: YALUN BIOTECHNOLOGY (BEIJING) Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |